版本:
中国

BRIEF-Bluebird Bio entered into a worldwide license agreement around its proprietary lentiviral vector platform with Novartis Pharma

May 2 Bluebird Bio Inc

* Bluebird bio inc- entered into a worldwide license agreement around its proprietary lentiviral vector platform with novartis pharma ag

* Bluebird bio inc- financial terms of agreement with novartis include an upfront payment to bluebird as well as milestone and royalty payments

* Bluebird bio-under terms novartis to non-exclusively license certain of co's patent rights to develop, commercialize chimeric antigen receptor t cell therapies for oncology Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐